No CrossRef data available.
Article contents
Addressing US Demand for Psychedelic Medicines in the Face of Scientific Uncertainty
Published online by Cambridge University Press: 15 October 2025
Abstract
Psychedelic medicines hold the promise of therapeutic benefit for many suffering from serious unmet mental health needs, leading to substantial demand even before these drugs receive FDA approval based on demonstrated safety and effectiveness for particular conditions. Recognizing FDA approval as the ideal path for psychedelics intended for medical use and drawing on lessons from medical marijuana, we encourage policymakers to balance the need for evidence, the importance of patient safeguards, and the desire for speed. They should increase support for psychedelic research, reject approaches that could inhibit that research, explore improvements to FDA’s existing pre-approval access pathway, and avoid politically motivated FDA approval of psychedelic medicines.
Keywords
Information
- Type
- Independent Articles
- Information
- Copyright
- © The Author(s), 2025. Published by Cambridge University Press on behalf of American Society of Law, Medicine & Ethics
References
Andrew Jacobs, “Veterans and Lawmakers Lobby in Bipartisan Push for MDMA Therapy,” New York Times, August 8, 2024, https://www.nytimes.com/2024/08/08/health/fda-mdma-therapy.html.Google Scholar
Andrew Jacobs, “F.D.A. Declines to Approve MDMA Therapy, Seeking More Study,” New York Times, August 9, 2024, https://www.nytimes.com/2024/08/09/health/fda-mdma-ptsd-delay.html.Google Scholar
Alexander Gaffney, “Trump May Hand Control of FDA over to RFK Jr. Here’s What That Could Mean for FDA and Industry,” Agency IQ by Politico, October 30, 2024, https://www.agencyiq.com/blog/trump-may-hand-control-of-fda-over-to-rfk-jr-heres-what-that-could-mean-for-fda-and-industry/.Google Scholar
Erin Schumaker, “RFK Jr. is bringing psychedelics to the Republican Party,” Politico, June 29, 2025, https://www.politico.com/news/2025/06/29/rfk-psychedelics-ecstasy-ibogaine-veterans-00429997Google Scholar
Olivia Goldhill and Meghana Keshavan, “Psychedelics proponents hope Trump administration will foster a new era,” STAT News, June 18, 2025, https://www.statnews.com/2025/06/18/fda-approval-psychedelics-rfk-jr-trump-allies-see-opening-mdma-psilocybin-mental-health-treatment/Google Scholar
Marks, Mason, “The Varieties of Psychedelic Law,” Neuropharmacology 226 (2023): 109399, https://doi.org/10.1016/j.neuropharm.2022.109399.CrossRefGoogle ScholarPubMed
Andrew Jacobs, “Texas OK’s $50 Million for Ibogaine Research,” New York Times, June 14, 2025, https://www.nytimes.com/2025/06/14/health/texas-psychedelics-ibogaine-veterans.htmlGoogle Scholar
Yaden, David B., Potash, James B., and Griffiths, Roland R., “Preparing for the Bursting of the Psychedelic Hype Bubble,” JAMA Psychiatry 79, no. 10 (2022): 934–44, https://doi.org/10.1001/jamapsychiatry.2022.2546.CrossRefGoogle ScholarPubMed
Zaretsky, Tamar Glatman et al., “The Psychedelic Future of Post-Traumatic Stress Disorder Treatment,” Current Neuropharmacology 22, no. 4 (2024): 636–735, https://doi.org/10.2174/1570159x22666231027111147.CrossRefGoogle ScholarPubMed
Raison, Charles L. et al., “Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial,” JAMA 330, no. 9 (2023): 843–53, https://doi.org/10.1001/jama.2023.14530.CrossRefGoogle ScholarPubMed
Brendan Borrell, “The Next Big Addiction Treatment,” New York Times, March 31, 2022, https://www.nytimes.com/2022/03/31/well/mind/psilocybin-mushrooms-addiction-therapy.html.Google Scholar
Rosenbaum, Daniel et al., “Psychedelics for Psychological and Existential Distress in Palliative and Cancer Care,” Current Oncology 26, no. 4 (2019): 225–26, https://doi.org/10.3747/co.26.5009.CrossRefGoogle ScholarPubMed
Mitchell, Jennifer M. et al., “MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study,” Nature Medicine 27, no. 6 (2021): 1025–33, https://doi.org/10.1038/s41591-021-01336-3;Google ScholarGoogle Scholar
Kai Kupferschmidt, “FDA Rejected MDMA-Assisted PTSD Therapy. Other Psychedelics Firms Intend to Avoid That Fate,” Science, August 12, 2024, https://www.science.org/content/article/fda-rejected-mdma-assisted-ptsd-therapy-other-psychedelics-firms-intend-avoid-fate.Google Scholar
Meghana Keshavan, “Rick Doblin, ‘unleashed,’ blasts FDA over Lykos drug rejection and turns to global push for MDMA therapy,” STAT News, August 17, 2024, https://www.statnews.com/2024/08/17/mdma-psychedelics-rick-doblin-lykos-exit/; Oshan Jarow, “MDMA’s federal approval drama, briefly explained,” Vox, June 4, 2024, https://www.vox.com/future-perfect/353752/mdma-fda-approval-hearing-lykos-blinding-misconduct-allegations; Will Stone, “FDA gives thumbs down to MDMA for now, demanding further research,” NPR, August 9, 2024, https://www.npr.org/sections/shots-health-news/2024/08/09/nx-s1-5068634/mdma-therapy-fda-decision-ptsd-psychedelic-treatment; Olivia Goldhill, “The inside story of how Lykos’ MDMA research went awry,” STAT News, June 9, 2024, https://www.statnews.com/2024/06/09/mdma-lykos-maps-psychedelics/; Will Stone, “Trouble for ecstasy? What MDMA’s FDA setback could mean for psychedelics,” NPR, June 13, 2024, https://www.npr.org/sections/shots-health-news/2024/06/13/nx-s1-4998523/mdma-fda-maps-psychedelic-research.Google Scholar
Kupferschmidt, “FDA Rejected MDMA-Assisted PTSD Therapy. Other Psychedelics Firms Intend to Avoid That Fate.”Google Scholar
Yaden, Potash, and Griffiths, “Preparing for the Bursting of the Psychedelic Hype Bubble.”Google Scholar
Turner, Erick H., “Esketamine for Treatment-Resistant Depression: Seven Concerns about Efficacy and FDA Approval,” Lancet Psychiatry 6, no. 12 (2019): 977–79.10.1016/S2215-0366(19)30394-3CrossRefGoogle ScholarPubMed
Dawn Megli, “The Ketamine Economy: New Mental Health Clinics Are a ‘Wild West’ with Few Rules,” NPR, January 30, 2024, https://www.npr.org/sections/health-shots/2024/01/30/1227630630/ketamine-infusion-clinic-mental-health-depression-anxiety-fda-off-label.Google Scholar
Hinkle, Jared T. et al., “Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis,” JAMA Psychiatry, September 4, 2024, e242546, https://doi.org/10.1001/jamapsychiatry.2024.2546.Google ScholarPubMed
Schlag, Anne K., Aday, Jacob, Salam, Iram, Neill, Jo C., and Nutt, David J., “Adverse Effects of Psychedelics: From Anecdotes and Misinformation to Systematic Science,” Journal of Psychopharmacology 36, no. 3 (2022): 258–272, https://doi.org/10.1177/02698811211069100.CrossRefGoogle ScholarPubMed
Smith, William R., Sisti, Dominic A., and Appelbaum, Paul S., “The Safety of Supported Psilocybin Use in Oregon,” Nature Medicine 30, no. 1 (2024): 17–18, https://doi.org/10.1038/s41591-023-02727-4.CrossRefGoogle ScholarPubMed
McGuire, Amy L. et al., “Pressing Regulatory Challenges for Psychedelic Medicine,” Science, 380, no. 6643 (April 28, 2023): 347–50, https://doi.org/10.1126/science.adg1324.CrossRefGoogle ScholarPubMed
US Food and Drug Administration, “Draft Guidance for Industry - Psychedelic Drugs: Considerations for Clinical Investigations,” June 2023, https://www.fda.gov/media/169694/download.Google Scholar
Goldy, Sean P et al., “Psychedelic Risks and Benefits: A Cross-Sectional Survey Study,” Journal of Psychopharmacology 39 no. 5 (2024): 436–452, https://doi.org/10.1177/02698811241292951.CrossRefGoogle ScholarPubMed
Yaden, Potash, and Griffiths, “Preparing for the Bursting of the Psychedelic Hype Bubble.”Google Scholar
Meling, Daniel et al., “Mind the Psychedelic Hype: Characterizing the Risks and Benefits of Psychedelics for Depression,” Psychoactives 3, no. 2 (2024): 215–34, https://doi.org/10.3390/psychoactives3020014.CrossRefGoogle Scholar
James Waldron, “Compass points to psychedelic therapy’s phase 3 depression win, but investors unimpressed,” Fierce Biotech, June 23, 2025, https://www.fiercebiotech.com/biotech/compass-points-psychedelic-therapys-phase-3-win-investors-unimpressed.Google Scholar
James Waldron, “Beckley Psytech’s psychedelic reduces depression symptoms in phase 2, triggering Atai merger,” Fierce Biotech, July 1, 2025, https://www.fiercebiotech.com/biotech/atais-psychedelic-reduces-depression-symptoms-phase-2-triggering-beckley-psytech-merger.Google Scholar
Humphreys, Keith et al., “Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money,” Annual Review of Psychology 76, no. 1 (2025): 143–65.10.1146/annurev-psych-020124-023532CrossRefGoogle ScholarPubMed
“Federal Food, Drug, and Cosmetic Act: New Drugs,” 21 U.S. Code § 355.Google Scholar
Food, Drug, and Cosmetic Act: Misbranded Drugs and Devices, 21 U.S. Code § 352; US Food and Drug Administration, “Facts About the Current Good Manufacturing Practice (CGMP),” https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practice-cgmp.Google Scholar
US Food and Drug Administration, “Postmarketing Requirements and Commitments: Frequently Asked Questions (FAQ),” https://www.fda.gov/drugs/postmarket-requirements-and-commitments/postmarketing-requirements-and-commitments-frequently-asked-questions-faq.Google Scholar
McGuire et al., “Pressing Regulatory Challenges for Psychedelic Medicine.”Google Scholar
Lynch, Holly Fernandez and Bateman-House, Alison, “Facilitating Both Evidence and Access: Improving FDA’s Accelerated Approval and Expanded Access Pathways,” Journal of Law, Medicine & Ethics 48, no. 2 (2020): 365–72.10.1177/1073110520935352CrossRefGoogle ScholarPubMed
Amy Baxter, “After an FDA Rejection, Here’s What’s next in the Psychedelics Pipeline,” BioPharma Dive, August 28, 2024, https://www.pharmavoice.com/news/fda-lykos-rejection-psychedelics-pipeline-cybin-mindmed-compass-incannex/725420/.Google Scholar
Agata Bodie, “Congressional Research Service Report R45414 - Expanded Access and Right to Try: Access to Investigational Drugs,” March 16, 2021, https://sgp.fas.org/crs/misc/R45414.pdf.Google Scholar
Lynch and Bateman-House, “Facilitating Both Evidence and Access.”Google Scholar
Folkers, Kelly, Chapman, Carolyn, and Redman, Barbara, “Federal Right to Try: Where Is It Going?,” Hastings Center Report 49, no. 2 (2019): 26–36.10.1002/hast.990CrossRefGoogle ScholarPubMed
Snyder, Jeremy, “Selling Hope: Exploitation and Unproven Stem Cell Interventions,” in Exploiting Hope: How the Promise of New Medical Interventions Sustains Us--and Makes Us Vulnerable (Oxford Academic, 2020), https://doi.org/10.1093/med/9780197501252.001.0001.CrossRefGoogle Scholar
“Expanded Access Program Report: Summary of Independent Assessment,” US Food and Drug Administration, May 2018, https://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UCM618903.pdf.Google Scholar
US Food and Drug Administration, Charging for investigational drugs under an IND, 21 CFR § 312.8.Google Scholar
Steven Boranian, “Ninth Circuit Rejects ‘Right To Try’ Hallucinogenic Drugs,” Drug & Device Law Blog, February 21, 2025, https://www.druganddevicelawblog.com/2025/02/ninth-circuit-rejects-right-to-try-hallucinogenic-drugs.html.Google Scholar
Nutt, David J., King, Leslie A., and Nichols, David E., “Effects of Schedule I Drug Laws on Neuroscience Research and Treatment Innovation,” Nature Reviews Neuroscience 14, no. 8 (2013): 577–85.Google ScholarPubMed
“An Open-Label Expanded Access Protocol for Esketamine Treatment of Subjects With Treatment Resistant Depression (TRD) Who Do Not Have Other Treatment Alternatives,” Clinical trial registration, September 13, 2023), https://clinicaltrials.gov/study/NCT04476446.Google Scholar
“Expanded Access Program for MDMA-Assisted Therapy for Patients with Treatment-Resistant PTSD (EAMP1),” Multidisciplinary Association for Psychedelic Studies, 2020, https://maps.org/mdma/ptsd/expanded-access/.Google Scholar
“Compassionate Use Policy,” Compass, https://compasspathways.com/our-work/compassionate-use-policy/ (as of July 4, 2025).Google Scholar
Compass, “Compassionate Use Policy.”Google Scholar
Aicher, Helena D., Schmid, Yasmin, and Gasser, Peter, “Psychedelics-assisted psychotherapy: Experiences with the limited medical use of LSD, MDMA, and psilocybin in Switzerland,” Die Psychotherapie 69 (2024): 98–106, https://doi.org/10.1007/s00278-024-00711-y.CrossRefGoogle Scholar
“Notice to stakeholders: Requests to the Special Access Program (SAP) involving psychedelic-assisted psychotherapy,” Health Canada, File No. 23-100122-763, February 27, 2023, https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html.Google Scholar
Richard, Jérémie, Garcia-Romeu, Albert, and Henningfield, Jack E, “Expanded access to psychedelic treatments: comparing American and Canadian policies,” General Psychiatry 38, no. 1 (2025): e101894, https://doi.org/10.1136/gpsych-2024-101894.CrossRefGoogle ScholarPubMed
Health Canada, “Requests to the Special Access Program (SAP) involving psychedelic-assisted psychotherapy.”Google Scholar
“Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists,” February 3, 2023, Australian Therapeutic Goods Administration, https://www.tga.gov.au/news/media-releases/change-classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrists; “Re-scheduling of psilocybin and MDMA in the Poisons Standard: questions and answers,” Australian Therapeutic Goods Administration, https://www.tga.gov.au/resources/publication/scheduling-decisions-final/notice-final-decision-amend-or-not-amend-current-poisons-standard-june-2022-acms-38-psilocybine-and-mdma/re-scheduling-psilocybin-and-mdma-poisons-standard-questions-and-answers.Google Scholar
“Becoming an authorized prescriber for unapproved therapeutic goods in Australia,” Australian Therapeutic Goods Administration, October 1, 2024, https://www.tga.gov.au/resources/guidance/becoming-authorised-prescriber-unapproved-therapeutic-goods-australia#information-for-hrecs-and-specialist-colleges.Google Scholar
“Unapproved products for multiple patients (Authorised Prescriber),” Australian Therapeutic Goods Administration, July 1, 2025, https://www.tga.gov.au/services/unapproved-products-multiple-patients-authorised-prescriber#frequently-asked-questions-faq.Google Scholar
Nutt, David J. et al., “The Australia story: Current status and future challenges for the clinical applications of psychedelics,” British Journal of Pharmacology (2024): https://doi.org/10.1111/bph.17398.CrossRefGoogle ScholarPubMed
Rossell, Susan L et al., “Why didn’t the TGA consult with Australian researchers and clinicians with experience in psilocybin-assisted psychotherapy for treatment-resistant major depressive disorder?,” Australian and New Zealand Journal of Psychiatry 57, no. 7 (2023): 935–936, https://doi.org/10.1177/00048674231172691.CrossRefGoogle ScholarPubMed
Nutt et al, “The Australia Story.”Google Scholar
Daniel Perkins, “A New Era of Psychedelic Medicine in Australia,” Regulatory Review, August 23, 2024, https://www.theregreview.org/2024/04/23/perkins-a-new-era-of-psychedelic-medicine-in-australia/.Google Scholar
Folkers, Kelly McBride, Bateman-House, Alison, and Robertson, Christopher T., “Paying for Unapproved Medical Products,” Wake Forest Journal of Law & Policy 11, no. 1 (2020): 85–117.Google Scholar
Marks, Mason, “State-Regulated Psychedelics on a Collision Course With FDA,” JAMA 330, no. 24 (2023): 2337–38, https://doi.org/10.1001/jama.2023.24762.Google ScholarPubMed
“Oregon Psilocybin Services,” Oregon Health Authority https://www.oregon.gov/oha/ph/preventionwellness/pages/oregon-psilocybin-services.aspx.Google Scholar
Natural Medicine Health Act of 2022, Title 12, Article 170, Colorado Revised Statutes § (2022).Google Scholar
Grant Stringer, “Oregon’s legal psilocybin clinics draw hundreds — mostly from out of state,” OPB, November 29, 2023, https://www.opb.org/article/2023/11/29/psilocybin-mushrooms-oregon-service-centers-price/.Google Scholar
Smith, Sisti, and Appelbaum, “The Safety of Supported Psilocybin Use in Oregon.”Google Scholar
“Oregon Psilocybin Services - Senate Bill 303 and Data Collection Information,” Oregon Health Authority, 2025, https://www.oregon.gov/oha/ph/preventionwellness/pages/psilocybin-sb303-and-data-collection.aspx.Google Scholar
Siegel, Joshua S. et al., “Psychedelic Drug Legislative Reform and Legalization in the US,” JAMA Psychiatry 80, no. 1 (2023): 77–83;10.1001/jamapsychiatry.2022.4101Google ScholarGoogle Scholar
Earp, Brian D. et al., “Racial Justice Requires Ending the War on Drugs,” American Journal of Bioethics 21, no. 4 (2021): 4–19.10.1080/15265161.2020.1861364CrossRefGoogle ScholarPubMed
Debra Kamin, “The Rise of Psychedelic Retreats,” New York Times, November 25, 2021, https://www.nytimes.com/2021/11/25/travel/psychedelic-retreat-ayahuasca.html; Nietzke-Spruill, Logan et al., “A landscape analysis of psychedelic retreat organizations advertising online,” PLOS One (2025), https://doi.org/10.1371/journal.pone.0321648.CrossRefGoogle Scholar
“FDA and Cannabis: Research and Drug Approval Process,” US Food and Drug Administration, https://www.fda.gov/news-events/public-health-focus/fda-and-cannabis-research-and-drug-approval-process.Google Scholar
Stains, Elena L. et al., “Medical Cannabis in the United States: Comparing 2017 and 2024 State Qualifying Conditions to the 2017 National Academy of Sciences Report,” Mayo Clinic Proceedings 9, no. 4 (2025): 100590;Google ScholarGoogle Scholar
Lisa N. Sacco, Joanna R. Lampe, and Hassan Z. Sheikh, The Federal Status of Marijuana and the Policy Gap with States (Congressional Research Service, May 2, 2024).Google Scholar
Cooper, Ziva D et al., “Challenges for Clinical Cannabis and Cannabinoid Research in the United States,” Journal of the National Cancer Institute 2021, no. 58 (2021): 114–122, https://doi.org/10.1093/jncimonographs/lgab009.Google Scholar
Megan Twohey, Danielle Ivory, and Carson Kessler, “As America’s Marijuana Use Grows, So Do the Harms,” New York Times, October 4, 2024, https://www.nytimes.com/2024/10/04/us/cannabis-marijuana-risks-addiction.html; Jayawardhana, Jayani et al., “Association of State Cannabis Legalization With Cannabis Use Disorder and Cannabis Poisoning,” JAMA Psychiatry, December 23, 2024, https://doi.org/10.1001/jamapsychiatry.2024.4145.Google Scholar
Nutt et al, “The Australia Story.”Google Scholar
Erin Schumaker, “RFK Jr. is bringing psychedelics to the Republican Party,” Politico, June 29, 2025, https://www.politico.com/news/2025/06/29/rfk-psychedelics-ecstasy-ibogaine-veterans-00429997Google Scholar
Tristan Manalac, “Makary Backs Psychedelics for Neuropsych, Promises Speedy Review,” BioSpace, May 20, 2025, https://www.biospace.com/fda/makary-backs-psychedelics-for-neuropsych-promises-speedy-reviewGoogle Scholar
“FDA commissioner says research on psychedelic treatment ‘top priority’,” NewsNation, May 16, 2025, https://www.newsnationnow.com/on-balance-with-leland-vittert/fda-commissioner-says-research-on-psychedelic-treatment-top-priority/Google Scholar
Erin O’Brien, “FDA Accepts, Grants Priority Review of NDA for MDMA-Assisted Therapy for PTSD,” Psychiatric Times, February 13, 2024, https://www.psychiatrictimes.com/view/fda-accepts-grants-priority-review-of-nda-for-mdma-assisted-therapy-for-ptsd.Google Scholar
Holly Fernandez Lynch, “How fast is too fast for drug review?,” Medpage Today, June 24, 2025, https://www.medpagetoday.com/opinion/second-opinions/116218.Google Scholar
Lynch, Holly Fernandez, Joffe, Steven, and McCoy, Matthew S., “The limits of acceptable political influence over the FDA,” Nature Medicine 27 (2021): 189–190, https://doi.org/10.1038/s41591-020-01200-w.Google Scholar
Sarah Karlin-Smith, “‘Highly Problematic’: Acting FDA Commissioner Paused Planned OK Of Novavax Shot,” Pink Sheet, April 4, 2025; Patricia J. Zettler et al., “FDA Review of Novavax’s COVID-19 Vaccine—Regulatory Integrity and Deviations From Standard Practice,” JAMA, June 9, 2025, https://jamanetwork.com/journals/jama/article-abstract/2835276; Andrew Dunn, “FDA head Makary’s short-lived CRL ask on KalVista’s drug raises more concerns of political intervention,” Endpoints News, June 27, 2025, https://endpoints.news/fda-head-makarys-intervention-attempt-on-kalvista-raises-concerns.Google Scholar
Paul Noth, “Weekly Cartoon: Altatude #11 Issue 22,” Alta Journal, February 11, 2023, https://www.altaonline.com/culture/cartoons/a42179654/weekly-cartoon-altatude-11-issue-22-paul-noth/Google Scholar
Barnett, Brian S., Mauney, Erin E., and King, Franklin, “Psychedelic-assisted therapy: An overview for the internist,” Cleveland Clinic Journal of Medicine, 92, no 3 (2025): 171–180, https://doi.org/10.3949/ccjm.92a.24032.CrossRefGoogle ScholarPubMed
US Food and Drug Administration, “Draft Guidance for Industry - Psychedelic Drugs: Considerations for Clinical Investigations.”Google Scholar
Tristan Manalac, “FDA Names Psychedelic Proponent as CDER Deputy Director, Top Spot Remains Open,” BioSpace, June 25, 2025, https://www.biospace.com/fda/fda-names-psychedelic-proponent-as-cder-deputy-director-top-spot-remains-open.Google Scholar
Stone, “Trouble for ecstasy? What MDMA’s FDA setback could mean for psychedelics.”Google Scholar
Marks, Mason and Shachar, Carmel, “Drug Scheduling Limits Access to Essential Medicines and Should Be Reformed,” Nature Medicine 29, no. 2 (2023): 294–97, https://doi.org/10.1038/s41591-022-02169-4.CrossRefGoogle ScholarPubMed
McGuire et al., “Pressing Regulatory Challenges for Psychedelic Medicine.”Google Scholar
Aday, Jacob S et al., “Addressing blinding in classic psychedelic studies with innovative active placebos,” International Journal of Neuropsychopharmacology, 28, no. 4 (2025): pyaf023, https://doi.org/10.1093/ijnp/pyaf023;Google ScholarGoogle Scholar
US Food and Drug Administration, “Draft Guidance for Industry - Psychedelic Drugs: Considerations for Clinical Investigations”; van Elk, Michiel and Fried, Eiko I., “History Repeating: Guidelines to Address Common Problems in Psychedelic Science,” Therapeutic Advances in Psychopharmacology 13 (2023): 20451253231198466.10.1177/20451253231198466CrossRefGoogle ScholarPubMed
Fernandez Lynch, “How fast is too fast for drug review?”Google Scholar
Polak, Tobias B., van Rosmalen, Joost, and Uyl – de Groot, Carin A., “Expanded Access as a Source of Real-world Data: An Overview of FDA and EMA Approvals,” British Journal of Clinical Pharmacology 86, no. 9 (2020): 1819–26.10.1111/bcp.14284CrossRefGoogle ScholarPubMed